Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Collier

Showing results (301-310 of 508) with videos related to

Pageof 51
Sort By:
Antimicrobial Agents and Chemotherapy|November 26, 1997
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapyG F Vanhove, H Kastrissios, J M Gries, et al.
HIV Clinical Trials|November 3, 2011
Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysisS Krishnan, K Wu, M Smurzynski, et al.
Biochemical Pharmacology|February 21, 2002
UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at termAbby C Collier, Natalie A Ganley, Malcolm D Tingle, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1994
Foscarnet for suppression of human immunodeficiency virus replicationC V Fletcher, A C Collier, F S Rhame, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
Placenta|February 15, 2020
Umbilical cord as an analytical matrix - A technical noteHayley R Price, Camron Chehroudi, Stuart J Knight, et al.
AIDS and Behavior|October 28, 2019
A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.SJane M Simoni, Kenneth Tapia, Sung-Jae Lee, et al.
The Journal of Infectious Diseases|November 14, 2009
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responsesYi Liu, John McNevin, Morgane Rolland, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 13, 2018
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulationJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
Pageof 51

Showing results (301-310 of 508) with videos related to

Sort By:
Pageof 51
Antimicrobial Agents and Chemotherapy|November 26, 1997
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapyG F Vanhove, H Kastrissios, J M Gries, et al.
HIV Clinical Trials|November 3, 2011
Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysisS Krishnan, K Wu, M Smurzynski, et al.
Biochemical Pharmacology|February 21, 2002
UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at termAbby C Collier, Natalie A Ganley, Malcolm D Tingle, et al.
Antimicrobial Agents and Chemotherapy|March 1, 1994
Foscarnet for suppression of human immunodeficiency virus replicationC V Fletcher, A C Collier, F S Rhame, et al.
Oncology|May 25, 2011
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysisSupriya Krishnan, Jeffrey T Schouten, Denise L Jacobson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 29, 2007
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas, Jiameng Zhang, Kevin Yarasheski, et al.
Placenta|February 15, 2020
Umbilical cord as an analytical matrix - A technical noteHayley R Price, Camron Chehroudi, Stuart J Knight, et al.
AIDS and Behavior|October 28, 2019
A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.SJane M Simoni, Kenneth Tapia, Sung-Jae Lee, et al.
The Journal of Infectious Diseases|November 14, 2009
Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responsesYi Liu, John McNevin, Morgane Rolland, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 13, 2018
Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulationJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
Pageof 51